Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc., despite the metadata request) on July 29, 2025. The filing reports the entry into a Fourth Amendment to a previously disclosed Agreement and Plan of Merger with Decoy Therapeutics Inc. and its subsidiaries.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the legal modification of merger terms and security holder rights.
Material Changes
The primary material change is the execution of the Fourth Amendment to the Merger Agreement, which modifies the conversion terms of Salarius's Series A and Series B Non-Voting Convertible Preferred Stock. These changes are designed to induce consent and conversion by holders of certain Decoy notes. Specific modifications include:
- Removal of the $2 million threshold requirement for triggering a "subsequent financing" adjustment.
- Change in conversion price adjustment calculation from a weighted average mechanism to the actual per share offering price in any subsequent financing.
- Elimination of the one-year limitation on conversion ratio adjustments; adjustments now apply until stockholder approval of conversion and meeting of Nasdaq initial listing standards.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard legal qualification that the descriptions of the amendment are not complete. The document notes that the Merger Agreement remains in full force and effect except as modified by this amendment.
Investor Verification Checklist
- Verify the full text of the Fourth Amendment (Exhibit 2.1) to understand the precise legal language of the conversion term changes.
- Review the Certificates of Designation for Series A and Series B Preferred Stock (Exhibits 2.2 and 2.3) to assess the impact on existing preferred shareholders.
- Confirm the status of Decoy Therapeutics' convertible and non-convertible notes and whether the amendment successfully induced the intended consents.
- Monitor subsequent filings for stockholder approval of the Preferred Stock conversion and the company's progress toward Nasdaq initial listing standards.